Feasability and safety of transfer from racemic methadone to (R)-methadone in primary care: Clinical results from an open study

World Journal of Biological Psychiatry

Volumn 10, Issue 3, 2009, Pages 217-224

  Soyka, Michae ^a,b   Zingg, Christina ^b  

^a UNIVERSITY OF MUNICH   (Germany)

^b Private Hospital Meiringen   (Switzerland)

Author keywords

Methadone; Opioid dependence; Substitution treatment

Indexed keywords

BENZODIAZEPINE; CANNABINOID; COCAINE; LEVOMETHADONE; METHADONE; OPIATE;

ADULT; AGITATION; ANXIETY; ARTICLE; CHOLESTASIS; CLINICAL TRIAL; CONCENTRATION LOSS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIZZINESS; DRUG FORMULATION; DRUG SAFETY; DRUG SUBSTITUTION; DRUG URINE LEVEL; DRUG WITHDRAWAL; FEASIBILITY STUDY; FEMALE; HEADACHE; HUMAN; MAJOR CLINICAL STUDY; MALE; OPEN STUDY; OPIATE ADDICTION; PAIN; PATIENT COMPLIANCE; PRIMARY MEDICAL CARE; RACEMIC MIXTURE; RESTLESSNESS; SIDE EFFECT; SWEATING; TACHYCARDIA; WITHDRAWAL SYNDROME;

ADULT; FEASIBILITY STUDIES; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; METHADONE; NARCOTICS; OPIOID-RELATED DISORDERS; PATIENT COMPLIANCE; PRIMARY HEALTH CARE; PROSPECTIVE STUDIES; STEREOISOMERISM; SUBSTANCE WITHDRAWAL SYNDROME;

EID: 68549130771     PISSN: 15622975     EISSN: 18141412     Source Type: Journal    
DOI: 10.1080/15622970802416057     Document Type: Article

References (43)

1. Amato L, Minozzi S, Davoli M, Vecchi S, Ferri M, Mayet S. 2004. Psychosocial combined with agonist maintenance treatments versus agonist maintenance treatments alone for treatment of opioid dependence. Cochrane Database of Systematic Reviews: CD004147.
2. Boulton DW, Arnaud V, DeVane CL. 2001. Pharmacokinetics and pharmacodynamics of methadone enantiomers after a single oral dose of racemate. Clin Pharmacol Ther 70:48-57.
3. Breen CL, Harris SJ, Lintzeris N, Mattick RP, Hawken L, Bell J. 2003. Cessation of methadone maintenance treatment using buprenorphine: transfer from methadone to buprenorphine and subsequent buprenorphine reductions. Drug Alcohol Depend 71:49-55.
4. Caplehorn JRM, Dalton MS, Haldar F, Petrenas AM, Nisbet JG. 1996. Methadone maintenance and addicts' risk of fatal heroin overdose. Subst Use Misuse 31:177-196.
5. Connock M, Juarez-Garcia A, Jowett S, Frew E, Liu Z, Taylor RJ, et al. 2007. Methadone and buprenorphine for the management of opiod dependence: A systematic review and economic evaluation. Health Technol Assess 11:9.
6. Crettol S, Déglon J-J, Besson J, Croquette-Krokar M, Hämmig R, Gothuey I, et al. 2006. ABCB1 and cytochrome P450 genotypes and phenotypes: Influence on methadone plasma levels and response to treatment. Clin Pharmacol Ther 80(6): 668-681.
7. Cronbach LJ. 1982. Designing evaluations of educational and social programs. San Francisco, CA: Jossey-Bass.
8. Darke S, Degenhardt L, Mattick R. 2007. Mortality amongst illicit drug users. Epidemiology, causes and intervention. Cambridge: Cambridge University Press.
9. De Vos JW, Ufkes JG, Kaplan CD, Tursch M, Krause JKA, van Wilgenburg H, et al. 1998. l-Methadone and d,l-methadone in methadone maintenance treatment for opiate addicts: A comparison of therapeutic effectiveness and plasma concentrations. Eur Addict Res 4:134-141.
10. Eap CB, Finkbeiner T, Gastpar M, Scherbaum N, Powell K, Baumann P. 1996. Replacement of (R)-methadone by a double dose of (R,S)-methadone in addicts: Interindividuell variability of the (R)/(S) ratios and evidence of adaptive changes in methadone pharmacokinetics. Eur J Pharmacol 50:385-389.
11. Eap CB, Buclin T, Baumann P. 2002. Interindividual variability of the clinical pharmacokinetics of methadone. Clin Pharmacokinet 41(14):1153-1193.
12. Ehret GB, Voide C, Gex-Fabry M, Chabert J, Shah D, Broers B, et al. 2006. Drug-induced long QT syndrome in injection drug users receiving methadone. Arch Intern Med 166:1280.
13. Foster DJ, Somogyi AA, Dyer KR, White JM, Bochner F. 2000. Steady-state pharmacokinetics of (R) and (S) methadone in methadone maintenance patients. Br J Pharmacol 50: 427-440.
14. Foster DJ, Somogyi AA, White JM, Bochner F. 2004. Population pharmacokinetics of (R)-, (S)- and rac-methadone maintenance patients. Br J Pharmacol 57:742-755.
15. Glasper A, Reed LJ, de Wet CJ, Gossop M, Bearn J. 2005. Induction of patients with moderately severe methadone dependence onto buprenorphine. Addict Biol 10:149-155.
16. Gowing L, Ali R, White J. 2006. Buprenorphine for the management of opiod withdrawal. Cochrane Database of Systematic Reviews: CD002025.
17. Greenwald MK, Schuh KJ, Stine SM. 2003. Transferring methadone-maintained outpatients to the buprenorphine sublingual tablet: a preliminary study. Am J Addict 12: 365-374.
18. Hser YI, Hoffman V, Grella CE, Anglin MD. 2001. A 33-year follow-up of narcotics addicts. Arch Gen Psychiatry 58: 503-508.
19. Hulse GK, English DR, Milne E, Holman CDJ. 1999. The quantification of mortality resulting from the regular use of illicit opiates. Addiction 94:221-229.
20. Judson BA, Horns WH, Goldstein A. 1976. Side effects of levomethadone and racemic methadone in a maintenance program. Clin Pharmacol Ther 20:445-449.
21. Justo D. 2006. Methadone-induced long QT syndrome vs. methadone-induced torsades de pointes. Arch Intern Med 166:2288.
22. Kharasch ED, Hoffer C, Whittington D, Sheffels P. 2004. Role of hepatic and intestinal cytochrome P450 3A and 2B6 in the metabolism, disposition, and miotic effects on methadone. Clin Pharmacol Ther 76(3):250-269.
23. Kreek MJ, Hachey DL, Klein PD. 1979. Stereoselective disposition of methadone in man. Lif Sci 24:925-932.
24. Kristensen K, Blemmer T, Angelo HR, Christrup LL, Drenck NE, Rasmussen SN, et al. 1996. Stereoselective pharmacokinetics of methadone in chronic pain patients. Ther Drug Monit 18:221-227.
25. Langendam MW, van Brussel GH, Coutinho RA, van Ameijden EJ. 2001. The impact of harm-reduction-based methadone treatment on mortality among heroin users. Am J Public Health 91:774-780.
26. Mattick RP, Kimber J, Breen C, Davoli M. 2004. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database of Systematic Reviews: CD002207.
27. Maxwell JC, Pullum TW, Tannert K. 2005. Deaths of Clients in methadone treatment in Texas: 1994-2002. Drug Alcohol Depend 78:73-81.
28. Mitchell TB, Dyer KR, Newcombe D, Salter A, Somogyi AA, Bochner F, et al. 2004. Subjective and physiological responses among racemic-methadone maintenance patients in relation to relative (S-) vs. (R-) methadone exposure. Br J Pharmacol 58:609-617.
29. Nakamura K, Hachey DL, Kreek MJ, Irving CS, Klein PD. 1982. Quantification of methadone enantiomers in humans using stable isotope-labeled (2H3)- and (2H8)methadone. J Pharmac Sci 71:40-43.
30. Scherbaum N, Finkbeiner T, Leifert K, Gastpar M. 1996. The efficacy of l-methadone and racemic methadone in substitution treatment for opiate addicts - a double-blind comparison. Pharmacopsychiatry 29:212-215.
31. Soyka M. 2008. Safety aspects in methadone maintenance treatment - part 1 (in german). Suchtmed 10:7-27.
32. Soyka M, Apelt SM, Wittchen HU. 2006a. The insufficient involvement of psychiatrists in substitution treatment (in German). Nervenarzt 77:1368-1372.
33. Soyka M, Apelt SM, Lieb M, Wittchen HU. 2006b. One year mortality rates of patients receiving methadone and buprenorphine maintenance therapy: A nationally representative cohort study in 2694 patients. J Clin Psychopharmacol 26:657-660.
34. Soyka M, Banzer K, Erbas B, Koller G, Backmund M. 2006c. Substitution treatment of drug addicts: Legal requirements and new evidence from therapy research (in German). Nervenheilkunde 25:286-294.
35. Soyka M, Kranzler HR, Berglund M, Gorelick D, Hesselbrock V, Johnson BA, et al. 2008. World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for biological treatment of substance use and related disorders, part I: Alcoholism. World J Biol Psychiatry 9:6-23.
36. Sullivan LE, Metzger DS, Fudala PJ, Fiellin DA. 2005. Decreasing International HIV transmission: The role of expanding access to opioid agonist therapies for injection drug users. Addiction 100:150-158.
37. Termorshuizen F, Krol A, Prins M, van Ameijden EJC. 2005. Long-term outcome of chronic drug use. Am J Epidemiol 161:271-279.
38. Totah RA, Allen KE, Sheffels P, Whittington D, Kharasch ED. 2007. Enantiomeric metabolic interactions and stereoselective human methadone metabolism. J Pharmacol Exp Ther 321(1):389-399.
39. United Nations Office for Drug Control. 2006.World drug report 2006. New York: United Nations Publications.
40. Verthein U, Ullmann R, Lachmann A, Dü ring A, Koch B, Meyer-Thompson H-G, et al. 2005. The effects of racemic D,Lmethadone and L-methadone in substituted patients - a randomized controlled study. Drug Alcohol Depend 80: 267-271.
41. Wittchen HU, Apelt SM, Soyka M, Gastpar M, Backmund M, Gö lz J, et al. 2008. Feasibility and outcome of substitution treatment of heroin-dependent patients in specialized substitution centers and primary care facilities in Germany: A naturalistic study in 2694 patients. Drug Alcohol Depend 95:245-257.
42. West SL, O'Neal KK, Graham CW. 2000. A meta-analysis comparing the effectiveness of buprenorphine and methadone. J Subst Abuse 12:405-414.
43. White JM, Lopatko OV. 2007. Opioid maintenance: A comparative review of pharmacological strategies. Expert Opin Pharmacother 8:1-11.